DEQUADIN ® Dequalinio

DEQUADIN ® is a drug based on Dequalinium chloride

THERAPEUTIC GROUP: Antiseptics of the oral cavity

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications DEQUADIN ® Dequalinio

DEQUADIN ® is indicated as an oral cavity antiseptic in the prevention and topical treatment of infections of the oral cavity and pharyngeal mucosa such as gingivitis, stomatitis, pharyngitis and tonsillitis.

Mechanism of action DEQUADIN ® Dequalinio

DEQUADIN ® is a drug based on Dequalinium, a quaternary ammonium cation generally present in the form of chloride salt, endowed with antiseptic and antibacterial activity.

Used topically in fact it interacts at the level of the oropharyngeal mucosa exerting an intense antibacterial action directed both against Gram positive and Gram negative bacteria, and against yeasts and fungi such as Candida albicans.

The aforementioned activity is supported by the chemical-physical characteristics of the Dequalinio chloride, which make it an excellent surfactant substance, able to interact with bacterial membranes, significantly increasing their permeability and thus altering the normal enzymatic activity up to the death of the microorganism.

The same chemical-physical properties prevent the oral Dequalinium from being absorbed by the pharyngeal or gastro-enteric gold mucosa, thus limiting the possible onset of clinically relevant systemic side effects

Studies carried out and clinical efficacy

DEQUALINIO AND ORAL HYGIENE

Oralprophylaxe. 1991 Dec; 13 (4): 133-41.

Study that shows how the treatment with Dequalinio chloride can deconstruct the dental plaque, facilitating the death of the microorganisms present there, thus ensuring greater hygiene of the oral cavity and reducing the possible incidence of infectious diseases.

THE USE OF DEQUALINIO IN GYNECOLOGICAL SCOPE

Arzneimittelforschung. 2002; 52 (9): 699-705.

An interesting study that demonstrates how the wide antibacterial spectrum with which Dequalinio is equipped would guarantee excellent antibiotic therapeutic activity in the treatment of gynecological infectious diseases.

APOPTOTIC PROPERTIES OF DEQUALINIO

Exp Biol Med (Maywood). 2012 Aug 1; 237 (8): 933-42.

Very interesting molecular study that tests the biological activity of Dequaline on tumor cells, highlighting how this active principle is capable of inducing apoptosis, activating specific signaling pathways. These evidences suggest to the various experts the need to better investigate the therapeutic potential of Dequalinio.

Method of use and dosage

DEQUADIN ®

250 mg tablets of Dequalinium chloride;

Solution for oral mucosa at 0.5% of Dequalinium chloride;

Spray for oral mucosa at 0.5% of Dequalinium chloride.

The dosage schedules for the use of DEQUADIN ® vary according to the chosen pharmaceutical format.

More precisely for DEQUADIN ® in tablets it is generally suggested to dissolve one tablet in the mouth every 3 hours; for DEQUADIN ® in spray or oral solution it is recommended to apply the drug every 3 hours using the appropriate dispenser or with a brush.

The aforementioned timing of recruitment may vary at medical discretion, especially in the subsequent maintenance phases.

Warnings DEQUADIN ® Dequalinio

The use of DEQUADIN ® should be preceded by a careful medical examination in order to clarify the origin of the pathology in progress and the eventual appropriateness of the chosen therapeutic protocol.

Prolonged use of DEQUADIN ® could lead to the onset of local adverse reactions and sensitization phenomena such as to require the suspension of the therapy in progress, also favoring the onset of microbial strains resistant to the therapy itself.

If the use of DEQUADIN ® did not determine appreciable results it would be advisable to consult your doctor and consider the possibility of reviewing the therapy in progress.

PREGNANCY AND BREASTFEEDING

Although there are currently no known major side effects for the fetus or the infant accidentally exposed to Dequalinio, we generally advise against the use of DEQUADIN ® during pregnancy and in the subsequent period of breastfeeding.

If this drug is essential for the patient's health, it would be advisable for her to be administered under the strict supervision of her gynecologist.

Interactions

Drug interactions worthy of clinical note are currently unknown.

Contraindications DEQUADIN ® Dequalinio

The use of DEQUADIN ® is contraindicated in patients who are hypersensitive to the active ingredient or to one of its excipients and in small patients below 3 years of age.